Mexrenoic acid | 41020-68-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Mexrenoic acid
• 英文别名: 3-[(7R,8R,9S,10R,13S,14S,17R)-17-hydroxy-7-methoxycarbonyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoic acid
• CAS: 41020-68-2
• 化学式: C₂₄H₃₄O₆
• 分子量: 418.5
• InChiKey: JBXXREPMUABISH-RGKMBJPFSA-N

物化性质

• 沸点：
  587.3±50.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  坎利酮 、 地西淄酮 、 Mexrenoic acid 、 丙利酸钾 、 螺内酯 、 (4Α,5Α,17Β)-4,5-环氧-3,17-二羟基-4,17-二甲基雄甾-2-烯-2-氰 、 美螺利酮 、 Oxprenoate 、 螺利酮 、 (7a,17b)-7-(乙酰基硫代)-4',5'-二氢-螺[雄甾-4-烯-17,2'(3'H)-呋喃]-3-酮 、 α-prorenone 、 依普利酮 生成 坎利酸
  参考文献：
  名称：

  Pharmaceutical preparation comprising an active dispersed on a matrix

  摘要：

  本发明涉及制药技术领域，描述了一种新型的有利的活性成分制备方法。该新型制备方法适用于生产大量的药物剂型。在新型制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油三酯和脂肪酸酯等一种或多种赋形剂组成的基质中。

  公开号：

  US20070122474A1

文献信息

• Compositions and methods for treating ocular diseases
  申请人：Yee Richard W.

  公开号：US10350223B2

  公开（公告）日：2019-07-16

  The compositions and methods disclosed herein provide for treatments of ocular disorders of the eye, such as ocular surface diseases as well as those associated with inflammation of internal cells and cell layers of the eye. The methods disclosed herein describe methods for treating ocular disorders, particularly dry eye disorders, comprising topically administering to an ocular region of a subject a composition comprising a pharmaceutically effective amount of at least one aldosterone antagonist or salt thereof and a pharmaceutically acceptable carrier. Included is a method for treating dry eye comprising topically administering to an ocular region of a subject a composition comprising spironolactone and hydroxypropyl methylcellulose; and reducing or preventing one or more symptoms or causes of dry eye.

  本文公开的组合物和方法可用于治疗眼部疾病，例如眼表疾病以及与眼部内部细胞和细胞层炎症相关的疾病。本文公开的方法描述了治疗眼部疾病，特别是干眼症的方法，包括向受试者的眼部局部施用组合物，该组合物包含药学上有效量的至少一种醛固酮拮抗剂或其盐和药学上可接受的载体。还包括一种治疗干眼症的方法，包括向受试者的眼部局部施用包含螺内酯和羟丙基甲基纤维素的组合物；以及减轻或预防干眼症的一种或多种症状或病因。
• UTILISATION DES COMPOSES ANTIMINERALOCORTICOIDES CONTRE LE SYNDROME DE SEVRAGE DES NARCOTIQUES
  申请人：Aventis Pharma S.A.

  公开号：EP0863760B1

  公开（公告）日：2001-12-05
• New use of antimineralocorticoid compounds against narcotic withdrawal syndrome
  申请人：Aventis Pharma S.A.

  公开号：US20040242552A1

  公开（公告）日：2004-12-02

  A method of treating narcotic withdrawal symptoms in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound having anti-mineralocorticoid activity sufficient to treat narcotic withdrawal sypmtoms.
• COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
  申请人：Yee Richard W.

  公开号：US20180050049A1

  公开（公告）日：2018-02-22

  The compositions and methods disclosed herein provide for treatments of ocular disorders of the eye, such as ocular surface diseases as well as those associated with inflammation of internal cells and cell layers of the eye. The methods disclosed herein describe methods for treating ocular disorders, particularly dry eye disorders, comprising topically administering to an ocular region of a subject a composition comprising a pharmaceutically effective amount of at least one aldosterone antagonist or salt thereof and a pharmaceutically acceptable carrier. Included is a method for treating dry eye comprising topically administering to an ocular region of a subject a composition comprising spironolactone and hydroxypropyl methylcellulose; and reducing or preventing one or more symptoms or causes of dry eye.
• US3946106A
  申请人：——

  公开号：US3946106A

  公开（公告）日：1976-03-23